This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Interest continues to grow in the delivery of aerosolized medications via high-flow nasal cannula (HFNC), largely because many patients requiring HFNC either require or will potentially benefit from inhaled medications.1,2 Over the last several years, several groups have conducted studies to demonstrate the feasibility and effectiveness of delivering aerosolized medications during HFNC; several have shown that transnasal delivery does result in pulmonary deposition of inhaled medications.3,-,5 In this issue of RESPIRATORY CARE, Colaianni-Alfonso6 et al report a study evaluating high-flow transnasal delivery of bronchodilators to subjects with COPD.
The authors reported that spirometry significantly increased both statistically and clinically. This is unsurprising based on similar …
Correspondence: Michael D Davis RRT PhD FAARC, 1044 W. Walnut Street R4-472, Indianapolis, Indiana. E-mail: MDD1{at}iu.edu
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$30.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
